Alert: Beware of new phone scam attempting to obtain personal information.
COVID-19: Get the latest updates, safety precautions, or learn how to schedule a video or in-person visit.

If you have a fever, cough or other symptoms of possible infection, notify us when you schedule an appointment and before you arrive. If you’re having a medical emergency, call 911. Upon arrival, everyone will receive a symptom and temperature check. Anyone with an elevated temperature will be connected with appropriate care.

Lung

  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  • A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
  • A221504: A Randomized, Double-Blind, Placebo-Controlled Pilot Study Of An Oral, Selective Peripheral Opioid Receptor Antagonist In Advanced Non-Small Cell Lung Cancer
  • A081105: Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
  • EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
  • PACIFIC-4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II,

    lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • For more information, contact Lauren Key, RN, BSN at 360-788-8238